Hannah Valantine
Director at BridgeBio Pharma, Inc. (BBIO); Director at CareDx, Inc. (CDNA)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $5.7M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jul 17SEC | CDNACareDx, Inc. | Sell Plan | 28,67936,786 held (−44%) | $36.14 | $1.0M | +76.2% |
| Jul 17SEC | CDNACareDx, Inc. | Sell Plan | 10036,686 held (−0%) | $36.55 | $4K | +74.2% |
| Jun 24SEC | BBIOBridgeBio Pharma, Inc. | Sell Plan | 2,80811,455 held (−20%) | $68.00 | $191K | -3.9% |
| Jun 24SEC | BBIOBridgeBio Pharma, Inc. | Sell Plan | 2,1969,259 held (−19%) | $68.57 | $151K | -4.7% |
| Jun 16SEC | CDNACareDx, Inc. | Sell Plan | 12,10336,686 held (−25%) | $23.11 | $280K | +175.5% |
| Mar 12SEC | BBIOBridgeBio Pharma, Inc. | Sell Plan | 8,6717,465 held (−54%) | $72.00 | $624K | -9.2% |
| Mar 3SEC | BBIOBridgeBio Pharma, Inc. | Sell Plan | 14,58418,365 held (−44%) | $67.08 | $978K | -2.6% |
| Mar 3SEC | BBIOBridgeBio Pharma, Inc. | Sell Plan | 10,9007,465 held (−59%) | $67.84 | $739K | -3.7% |
| Nov 14SEC | BBIOBridgeBio Pharma, Inc. | Sell | 25,4847,465 held (−77%) | $66.07 | $1.7M | -1.1% |
- Sell
Director Hannah Valantine sold $1.0M of CDNA at $36.14 — cuts the stake by 44%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Hannah Valantine sold $4K of CDNA at $36.55 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Hannah Valantine sold $191K of BBIO at $68.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Hannah Valantine sold $151K of BBIO at $68.57 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Hannah Valantine sold $280K of CDNA at $23.11 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Hannah Valantine sold $624K of BBIO at $72.00 — cuts the stake by 54%; pre-scheduled 10b5-1 plan sale.